AroCell’s 2021 Annual Report published

AroCell today announces that the Annual Report for 2021 is now available on the company’s website: www.arocell.com.

The Annual report is available on the following link: https://arocell.com/sv/financial-report/
The report is available in Swedish only.

This information was submitted for publication through the agency of Anders Hultman, on April 7, 2022, at 12:00.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com